Ainos, Inc. — 2015 Form 10-K Summary
Registrant and period: The supplied filing is for Amarillo Biosciences, Inc. (OTC: AMAR), not Ainos, Inc. It reports the fiscal year ended December 31, 2015; it is not a standalone fourth-quarter report. The company emerged from Chapter 11 and adopted fresh-start accounting effective November 20, 2014, so predecessor and successor results are not directly comparable.
Business context
Amarillo was a small biopharmaceutical development company focused on low-dose oral interferon for human diseases, including influenza, hepatitis, and thrombocytopenia. It also held rights to Maxisal, a dry-mouth supplement, and was exploring other potential business lines. The company reported four employees and three consultants.
Financial performance and position
| Metric | FY 2015 / December 31, 2015 | Comparable information disclosed |
|---|---|---|
| Revenue | $1,975 | $0 in the 2014 successor and predecessor periods shown in the audited statements |
| Operating expenses | $521,796 SG&A; no R&D expense | 2014 SG&A was $69,707 for the successor period and $496,269 for the predecessor period; predecessor R&D was $15,270 |
| Net income (loss) | $(521,874) | 2014 successor loss $(70,155); predecessor income $2,909,870, including $3,422,850 debt-forgiveness income |
| Operating cash flow | $(366,414) | 2014 successor-period cash use $(53,042); predecessor-period cash use $(501,939) |
| Cash and equivalents | $21,138 | $318,556 at December 31, 2014 |
| Total assets / liabilities | $117,195 / $589,237 | $421,535 / $452,277 at December 31, 2014 |
| Working capital | Deficit of $549,945 | 2014 surplus of $33,161, as stated in MD&A |
| Stockholders’ deficit | $472,042 | $30,742 at December 31, 2014 |
Reported gross margin was $1,975, with no cost of revenue recorded. The company’s notes say the sales-related transaction was exploratory and that associated costs and other accounting details were not yet known. The filing also states elsewhere that no products were sold and no revenue was recognized; these disclosures are inconsistent.
Cash decreased by $297,418 during 2015. Investing activities used $11,578, and financing activities provided $80,574, reported as a stock-subscription premium. The company had $384,555 in related-party notes payable, all classified as current at year-end, plus $144,426 payable to a related party. Total current liabilities were $589,237.
Material changes and unusual items
- SG&A declined by $44,180, or about 8%, from the prior-year amount cited in MD&A; the filing attributes much of the decrease to lower reorganization expense. R&D fell to zero.
- The 2014 reported profit included substantial debt-forgiveness income from the bankruptcy reorganization; there was no debt-forgiveness income in 2015.
- The company completed its Chapter 11 exit in January 2015. It stated that reorganization reduced debt from $4.8 million to $452,277, but year-end 2015 total liabilities had risen to $589,237.
- Cash fell from $318,556 to $21,138, while the company reported a $549,945 working-capital deficit.
- On July 31, 2015, the company received $225,000 related to subscriptions for 1.2 million shares. It recorded $80,574 as additional paid-in capital and $144,426 as payable to CEO Stephen Chen. No common shares were reported as issued during 2015. The related-party payable was converted to a demand convertible note on January 11, 2016.
- The first $37,811 payment on a $150,000 secured related-party obligation was due September 1, 2015 and remained unpaid at year-end; the company reported no demand for payment. A separate $234,555 related-party debt was payable on demand, also with no demand reported.
Outlook, risks, and contingencies
- The independent auditor and management disclosures raise substantial doubt about the company’s ability to continue as a going concern. The company depended on additional financing to fund operations and projected losses.
- Management estimated post-reorganization financing needs of $1 million to $1.6 million. The filing says Yang investors had indicated willingness to assist but were not obligated to provide funding. Commercialization and new product development were not expected to produce meaningful revenue before the second quarter of 2017, or later.
- The former supplier of natural human interferon stopped production in 2012. The company was seeking alternatives; it said prior studies may need to be repeated using recombinant interferon, at significant cost and time. Its agreement with Intas Pharmaceuticals might be terminated because of supply problems.
- The company’s patents were a key asset, but the filing warned that they may have limited commercial value without financing, a replacement supply, further studies, and regulatory approvals. Three issued patents were stated to expire between 2018 and 2021.
- Maxisal’s supply chain was also impaired by higher prices and minimum-purchase requirements for a raw material. The company reported no ongoing clinical studies and no related clinical-trial payment obligations in 2015.
- The company reported no pending litigation. It disclosed approximately $20.5 million of federal net operating loss carryforwards, but a full valuation allowance was recorded; use may be limited by ownership changes and other factors.
- The company reported effective disclosure controls and internal control over financial reporting based on management’s assessment; the auditor did not provide an attestation on internal controls.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-K names Amarillo Biosciences, Inc., not Ainos, Inc.
- Reconcile the $1,975 revenue and gross-margin disclosure with the notes stating that no sales occurred and that transaction costs and accounting were still under review.
- Review near-term liquidity, the company’s financing plan, and whether related parties or other investors actually provided additional capital.
- Verify the status and payment terms of the $150,000 secured debt, the $234,555 demand debt, and the $144,426 CEO-related obligation converted to a note after year-end.
- Assess whether an alternative interferon source, funding for studies, regulatory progress, and commercialization are achievable before key patent protections expire.
- Account for fresh-start reporting when comparing results with 2014, and distinguish the 2014 reorganization-related debt-forgiveness gain from recurring operating performance.